Dr Eleni Efstathiou (University of Athens, Athens, Greece), Prof Fred Saad (University of Montreal Hospital Center, Montreal, Canada) and Prof Oliver Sartor (Tulane Cancer Center, New Orleans, USA) discuss the latest developments in diagnostics and combination therapies for mCRPC.
Initially, they discuss the phase III VISION study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer. They then discuss the ACIS study and what it means for mCRPC patients. Prof Sartor and Dr Efstathiou also talk about circulating tumour DNA fraction to independently predict clinical outcomes in patients with metastatic castration-resistant prostate cancer. Dr Efstathiou mentions the ODENZA study which is then further discussed. In the end, they talk about the future of mCRPC research and other studies of significance regarding it.
|Results from the VISION Trial|
|Results from the ACIS trial|
|The future with regards to treatment of elderly patients|
|Combination therapies for mCRPC|
|Bipolar androgen therapy (BAT) and nivolumab for mCRPC patients|
|Results from ODENZA Trial|
|ctDNA% to independently predict for clinical outcomes in patients with mCRPC|
|Take home message from ASCO 2021|
This programme has been supported by an unrestricted educational grant from Janssen.